Authors’ Disclosure Statement: Dr. Rosenberg reports that he is a consultant to and receives royalties from Zimmer Biomet. The other authors report no actual or potential conflict of interest in relation to this article.
Dr. Sartawi is Chairman, Department of Orthopaedics, Christie Clinic, Champaign, Illinois. Dr. Zurakowski is Director of Biostatistics, Department of Orthopedic Surgery, Boston Children's Hospital, Boston, Massachusetts. Dr. Rosenberg is a Senior Orthopaedic Surgeon, Rush Medical College, Chicago, Illinois.
Address correspondence to: Muthana Sartawi, MD, Department of Orthopaedics, Christie Clinic, 2110 Fox Drive, Champaign, IL 61820 (email, sartawimd@gmail.com).
Muthana Sartawi, MD David Zurakowski, PhD and Aaron Rosenberg, MD . Implant Survivorship and Complication Rates After Total Knee Arthroplasty With a Third-Generation Cemented System: 15-Year Follow-Up. Am J Orthop. March 28, 2018
TAKE-HOME POINTS
TKA has a high success rate in pain relief and restoration of function in patients with severe osteoarthritis.
NexGen (Zimmer Biomet) knee implants showed excellent functional outcomes at 15 years.
There are no significant differences in functional outcomes between the PS and CR knee systems.
NexGen knee implants showed excellent longevity and survivorship at 15-year follow-up with no evidence of aseptic loosening.
There is an increased incidence of knee osteoarthritis in the younger population (<55 years of age).
References
ABSTRACT
This work is a retrospective cohort study evaluating patients who had undergone third-generation cemented total knee arthroplasty (TKA) with prostheses (NexGen, Zimmer Biomet) utilizing posterior-stabilized (PS) and cruciate-retaining (CR) designs at a single center at their 15-year follow-up.
The purpose of this study is to determine the functional knee scores, reoperations, and long-term survivorship for patients with the NexGen Zimmer Biomet Knee system at the 15-year follow-up. In total, 99 patients who had undergone primary TKA were followed for 15 years.
At the 15-year follow-up, survivorship in both study groups was similar: 98% for PS TKAs and 100% for CR TKAs. The 2 groups also showed similar functionality: 80% of the PS implants and 89% of the CR implants were associated with no or mild pain (P = .40). Reoperation rates were 2% for the PS group and 0% for the CR group (P = .38). No differences in any of the outcomes analyzed were observed between patients who had CR TKA and those who had undergone PS TKA.
Our study found no significant differences in functional outcomes between PS and CR NexGen knee implants. Patients treated by both methods showed excellent longevity and survivorship at the 15-year follow-up.
